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Abstract Severe infection of infants with respiratory
syncytial virus (RSV) is a leading cause of morbidity in the
developed world and mortality in the developing world.
Prophylaxis using palivizumab in infants at risk for severe
RSV disease reduces the rate of hospitalisation in this
population of children. To ensure complete prophylaxis,
infants must receive monthly doses over the winter season.
To improve parental convenience, the Synacare pro-
gramme was implemented in Ireland and the Netherlands.
Synacare is now a longstanding programme in which
palivizumab is administered in the home setting by skilled
nurses. Protocols and procedures described here illustrate
the efficiency and acceptability of the home delivery ser-
vice of RSV disease prophylaxis. Post-administration sur-
veys have indicated a high level of parental satisfaction
with the programme. At-home paediatric programmes like
Synacare may serve as an alternative to burdensome
monthly hospital visits and may lead to enhanced clinical
outcomes.
Introduction
Infection with respiratory syncytial virus (RSV) occurs in
most children by 2 years of age [1, 2]. The virus is highly
contagious and is spread through close exposure to indi-
viduals with infection and through contact with fomites or
virus-laden large airborne particles [3–5]. Although most
children experience only mild (or no) symptoms, severe
RSV disease may require hospitalisation [6, 7] and may be
associated with an increased risk of wheezing and/or
asthma later in life [8–10]. Severe RSV-associated lower
respiratory tract disease is an important cause of mortality
among young children in the developing world [11].
Risk factors for severe RSV disease in children include
preterm birth [12–14], the presence of chronic lung disease
of prematurity (CLDP; also known as bronchopulmonary
dysplasia [BPD]) and haemodynamically significant con-
genital heart disease (hsCHD) [15, 16]. The rate of RSV
infections throughout the year typically changes in a sea-
sonal manner that is dependent on a number of geographic
and climatic factors; virulence per RSV season may also
vary [17]. The RSV season in temperate climates of the
Northern Hemisphere generally begins in October and
extends until March or April, with a peak between
December and February [17, 18], although some annual
variation exists [19]. The somewhat predictable nature of
the RSV season onset permits nurses, physicians, and other
healthcare workers to prepare for an expected increase in
RSV infection cases.
Currently, no vaccine is available for the prevention of
RSV infection. The management of severe RSV infection
generally consists of supportive measures, such as main-
tenance of adequate hydration and oxygenation [20].
Palivizumab (Synagis, MedImmune, LLC, and AbbVie
Inc.), a humanised monoclonal antibody specific for the
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RSV F protein, inhibits binding of the virus to host cells
and fusion of infected cells with adjacent cells [21]. Pro-
phylaxis with palivizumab has been shown to decrease the
rate of hospitalisation due to RSV-associated lower respi-
ratory tract disease in the population of infants born pre-
maturely [B35 weeks gestational age (wGA)] and children
\24 months of age with BPD or hsCHD [22, 23].
Palivizumab is administered intramuscularly (15 mg/kg)
to infants monthly beginning before the expected start of
the RSV season [24, 25]. Maintenance of serum anti-RSV
immunoglobulin concentrations during the RSV season is
necessary for decreasing the risk of severe RSV disease
[21].
Outpatient administration of palivizumab typically
occurs in the hospital, physician’s office, or specifically
dedicated clinic, which requires transportation of the infant
to the site of prophylaxis administration. For some fami-
lies, economic, logistical, and/or work considerations may
make it difficult to bring their infant to receive the monthly
injection, especially in cases of multiple births, other
comorbidities, long travel distances, or if young siblings
need to be brought to the visit. These issues have the
potential to decrease adherence, and thus adversely affect
the maintenance of protective serum palivizumab concen-
trations in these at-risk infants.
Home-based palivizumab administration has been
shown to reduce the number of RSV-associated and all-
cause hospitalisations compared with the administration of
palivizumab in the medical office or clinic [26, 27]. The
potential reasons for this reduction have been postulated to
be increased adherence with palivizumab prophylaxis and
removal of the requirement to enter a busy hospital or
physician’s office during the RSV endemic months,
thereby reducing the risk of pathogen exposure. For these
reasons, a programme of home-based palivizumab admin-
istration (Synacare, AbbVie) was established in the
Netherlands in 2003 and in Ireland in 2008, where previ-
ously parents had to attend monthly prophylaxis clinics at
the hospital. To date, these two countries are the only ones
to have a national home-based delivery programme.
Trained nurses visit the homes of infants to administer
palivizumab. The similarities and differences between the
Irish and Dutch Synacare programmes, documented in
this review, illustrate the idiosyncrasies and potential
advantages of each system.
RSV prophylaxis overview
In Ireland and the Netherlands, palivizumab is indicated for
children born at B35 wGA and 32 wGA, respectively, and
\6 months of age at the onset of the RSV season; children
\2 years of age requiring treatment for BPD within the
last 6 months; and children\2 years of age with hsCHD.
The presumed start of the RSV season, and the start of
prophylaxis with palivizumab, is often set by regional
healthcare authorities based on historical data in those
areas. A recent analysis of Canadian data found that the
most effective method of determining the start of the RSV
season was through the surveillance of virology data from
local laboratories, assuming a 2-day turnaround in labora-
tory results [28]. In Ireland and the Netherlands, the RSV
season usually extends from September/October through
March/April and palivizumab prophylaxis typically begins
in early October. In Ireland, prophylaxis begins during the
first week of October or after confirmation of increasing
positive cases by the National Virus Reference Laboratory.
Infants eligible for RSV prophylaxis
Eligibility for palivizumab and the Synacare service is
decided by the attending paediatrician; in Ireland, each
hospital has its own internal RSV prophylaxis eligibility
guidelines. Further, in Ireland, all prescriptions are reim-
bursed, with some families contributing to the cost via a
capped monthly pay scheme. The cost of prophylaxis for
Irish parents is partly or fully covered by the Irish health-
care system under a special social services insurance
scheme. Some families with limited financial income are
eligible for full drug cost coverage by the Health Services
Executive (HSE) Medical Card [29]. Under the Drugs
Payment Scheme (as of January 2013), parents with higher
incomes pay a capped price of €144 per month for family
medications, which include palivizumab prophylaxis. This
charge covers the entire family, meaning that if the infant
or any other member of the household receives additional
medications during this month, the household charge is still
capped at €144.
In the Netherlands, there is national guidance [‘‘Stand-
punt NVK ‘Passieve immunisatie tegen RSV-ziekte’’
(Dutch Paediatric Society Position on Passive Immunisa-
tion Against RSV Disease) and ‘‘Wijziging regeling
zorgverzekering’’ (Amendments to Insurance Regulations)]
that describes the population of patients that should receive
palivizumab prophylaxis (Table 1) [30] and those who are
eligible for reimbursement [31]. In the Netherlands, it is a
requirement for all citizens to have health insurance, which
covers the cost of palivizumab according to these
guidelines.
Issuance of the prescription
In Ireland (Fig. 1a), palivizumab is prescribed on a ‘High
tech’ paper prescription and is usually limited to five doses
if the baby is born before the RSV season commences (a
sixth dose may be prescribed to particularly vulnerable
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infants during a prolonged RSV season). ‘High tech’
medicines are generally prescribed or initiated in the hos-
pital and supplied through community pharmacies. The
Synacare provider, in communication with par-
ents/guardians, ensures that the parent delivers the pre-
scription to their designated pharmacy and helps the parent
inform the pharmacist of the approximate weight of the
patient. The Synacare service then reminds the par-
ents/guardians to collect the prescribed palivizumab 2 days
before the first scheduled visit and each subsequent visit.
In the Netherlands (Fig. 1b), the prescription is elec-
tronically generated and issued to the care provider
wholesaler who confirms that the prescription is reim-
bursable with the health insurance company of the patient.
Once reimbursement is confirmed, palivizumab is shipped
to the appropriate pharmacy. The prescription, in all but
exceptional cases, is one 100-mg vial and one 50-mg vial
of palivizumab to ensure sufficient drug is available for
dosing. The palivizumab is collected from the patient’s
pharmacy by the Synacare nurse just before each home
visit. Unused, non-reconstituted palivizumab is stored by
the parent. Subsequent doses are coordinated by the
Synacare service and the local pharmacy with approval
from the insurance company.
In-home administration
The in-home processes for the administration of palivizu-
mab in Ireland and the Netherlands are similar in many
respects, but also possess a number of unique characteris-
tics. The duration of the home visit in both Ireland and the
Netherlands is &1.0–1.5 h for the first visit (which
includes a parental educational component) and then
0.75–1 h for each subsequent visit.
Typically, infants born during the RSV season in Ireland
receive their first dose of palivizumab in the hospital,
preferably 2 days before discharge, whereas subsequent
doses may be given at home. In contrast, infants born in the
Netherlands are registered in the Synacare service during
their initial hospital stay and will receive palivizumab for
the first time at home. In both countries, infants who
require prolonged hospitalisation during the winter months
receive palivizumab monthly whilst in the hospital, and in
cases where infants are considered to be at high risk
because of conditions such as severe cardiac comorbidities,
the attending physician may decide that prophylaxis should
be medically supervised in a hospital environment, and
therefore, all doses may be administered in the hospital
setting. For infants born outside the winter season, the
hospital discharging nurse (or other appropriate nurse) is
responsible for informing the infant’s parents/guardians
regarding the RSV prophylaxis home service for which the
infant is eligible. The parents are also given information
regarding RSV infection and RSV prevention measures.
Parents of infants who were born outside of the RSV sea-
son receive a phone call from the Synacare home service
team just before the onset of the RSV season. Through this
initial call, the team confirms that the correct infant
information is recorded, describes the home service,
schedules the first appointment, and gives information
regarding the prescription for palivizumab.
An informal home-risk assessment is completed by the
nurse for all first visits. A general assessment includes a
verbal consent and parent signature (to proceed with
injection), a general assessment of the infant’s physical
condition, a baseline check (body temperature, respiratory
rate and heart rate), calculation of dose based on infant
weight and preparation and injection of palivizumab. An
additional 10–20 min is allotted to assess any potential
Table 1 Populations eligible for palivizumab prophylaxis in Ireland and the Netherlands
Characteristic Ireland The
Netherlands
Born B32 wGA and\6 months at the start of the RSV season All All
Born\1000 g and\6 months at the start of the RSV season All All
\1 year of age with BPD or documented evidence of pulmonary hypertension All All
\2 years of age and requires supplementary oxygen treatment for BPD or continuing to require respiratory
medication
All All
\2 years of age with CHDa All All
\1 year of age with haemodynamically significant CHD All All
\1 year of age with a serious immune deficiency Someb Someb
\1 year of age with a serious lung pathology as a result of cystic fibrosis Someb All
32–35 wGA Someb No
BPD bronchopulmonary dysplasia, CHD congenital heart disease, RSV respiratory syncytial virus, wGA weeks gestational age
a Only 10 % of infants with CHD require palivizumab prophylaxis in their second year of life
b Selected hospitals
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adverse reactions and to complete any administrative
paperwork, which is often recorded electronically.
In Ireland and the Netherlands, the Synacare nurses are
responsible for reporting all adverse events (AEs), includ-
ing those that may not be serious and those that may not be
considered to be related to palivizumab administration. In
the Netherlands, the Synacare nurse reports all AEs to the
pharmacy, which also links to an AbbVie database (for
pharmacovigilance reporting). This process may diminish
the underreporting of AEs [32, 33]. However, the incidence
of AEs related to palivizumab injection is generally low
[22, 23]. In Ireland, Synacare homecare nurses are also
Appointment  is made for next visit date and me, if applicable 
The paent electronic report is available on a secure online system for all approved healthcare providers to review 
All waste is appropriately collected and removed 
Nurse observes the paent and electronically completes visit report and reports any adverse events 
Nurse speaks to parent for 20 minutes whilst the palivizumab reconstutes 
Once the paent is conﬁrmed as physically ﬁt to recieve palivizumab the nurse calculates the palivizumab dosage and the appropriate 
amount of palivizumab is reconstuted 
Nurse physically examines paent and takes paent weight.  If the nurse has any serious concerns she contacts prescribing physician  
At the ﬁrst visit, the paent details are veriﬁed, the service is explained, and informed consent is provided from the parents to have 
their child included in the Synacare service 
2 days before the visit, the nurse calls the parent to conﬁrm that palivizumab is at the home and is being stored correctly in the 
refrigerator 
Parents collect palivizumab from their local pharmacy and store at 2o to 8oC 
Synacare sends a text message to parent 1 week before the visit to remind parents to collect the palivizumab prescripon from the 
pharmacy 
Synacare calls parents to schedule the ﬁrst visit and conﬁrms preferred pharmacy for collecon of palivizumab 
Synacare receives paent details 
Parent informed of Synacare service and given informaon package 
"High tech" prescripon generated and sent to parent 
Nurse electronically or manually refers paent to service 
Physician/nurse idenﬁes eligible paent a
Fig. 1 Synacare RSV prevention homecare flow chart: a Ireland, b The Netherlands. RSV respiratory syncytial virus
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responsible for reporting all AEs to the local AbbVie
pharmacovigilance officer who then reports the events to
the Health Products Regulatory Authority.
In Ireland, subsequent visits are scheduled and con-
firmed 1 week in advance of the proposed visit to ensure
compliance. If the most recent weight is not available from
the parent, the weight will be estimated for the first pre-
scription based on the most recent hospital records. The
infant will then be weighed before administration of pali-
vizumab at home. To ensure that prophylaxis is adminis-
tered on the correct date, up to three different nurses may
visit the infant and parents during the RSV season to
accommodate the nurses’ availability. Before visiting the
home, each nurse electronically reviews patient details and
notes. The day before the visit, the nurse confirms the visit
time and ensures that palivizumab has been collected and is
being refrigerated in the infant’s home. Approximately ten
nurses are involved in the Synacare programme in Ire-
land, each of whom can perform four (rural) to six (city)
visits per day.
All Synacare homecare nurses are fully qualified pae-




provider of direct-to-patient services and AbbVie before
commencing any homecare visits. In addition, the home-
care service is able to liaise with a hospital-based clinical
nurse specialist based in the main paediatric hospital in
Ireland who coordinates the prophylaxis programme to
ensure that infants scheduled for home administration still
receive prophylaxis if they are hospitalised after discharge
to ensure continuity of coverage.
For additional training purposes, a twice-yearly meeting
of hospital-based neonatal nurses and Synacare neonatal
and paediatric nurses with responsibility for severe RSV
disease prophylaxis is held in Ireland to exchange experi-
ences regarding best practices. One meeting is held at the
beginning of the RSV season and a review meeting takes
place at the end of the season.
The home service in the Netherlands is led by the
individual nurse assigned to a specific patient. Homecare
nurses in the Netherlands have a great deal of indepen-
dence in the planning and execution of the home visit
process. The patient interaction begins with contact by a
nurse from the home service and/or from the hospital
shortly before discharge. The paediatrician usually speaks
with parents on a weekly basis. All attempts are made to
ensure that the same nurse is assigned to the same infant for
all visits. This allows the nurse to consistently monitor the
infant during the entire series of injections and may provide
parents with a greater level of comfort. An appointment for
the next visit is scheduled before departure from the home
and parents complete a home visit assessment form during
the first visit. Approximately 60 nurses in the Netherlands
are involved in the Synacare programme and because
travel distances are relatively short, nurses can perform 7 to
8 visits per day.
In the Netherlands, annual training of nurses is con-
ducted by AbbVie. The nurses have neonatal care experi-
ence and regular regional meetings allow nurses to increase
their knowledge base regarding best practices that reduce
RSV infection. In addition, nurses are made aware that any
question from parents that cannot be adequately answered
should be referred to the hospital or the paediatrician.
Parent/guardian education
The education of parents is of major importance to the
health of the infant. The role of the home nurse is critical in
reinforcing the messages about practices that will help
reduce the risk of RSV infection [34, 35]. Before discharge,
parents meet with a nurse responsible for discharge plan-
ning. Greater understanding of the need for RSV prophy-
laxis for at-risk infants may help to increase adherence,
reduce stress and anxiety, and enhance clinical outcomes.
Parents are provided with written material advising them of
the importance of reducing the risk of RSV infection and
explaining the Synacare programme.
It is important that parents understand the rationale for
palivizumab administration and the requirement for
monthly dosing to maintain antibody levels. Information
shared with the parents includes discussions regarding the
disease state, RSV prophylaxis, and how the medication
works [22, 23, 36]. Parents are also advised that palivizu-
mab administration will not prevent every respiratory ill-
ness, such as influenza, and that concomitant
administration of palivizumab and childhood vaccines is
not contraindicated [37].
The importance of prevention measures to decrease the
number of infections during annual periods of peak RSV
infection is emphasised. Parents are advised to wash hands,
to avoid crowds, and to avoid their child’s exposure to
tobacco smoke [34]. Parents are directed toward online
information regarding RSV and the prevention of infection
(Table 2) and toward locally produced, physician-endorsed
paper-based information. It is important that the websites
identified contain accurate and up-to-date information that is
written at a level that most parents can understand and use.
In Ireland, parental education regarding the reduction of
RSV infection begins with the hospital nurse and, from the
moment the baby enters the neonatal intensive care unit
(ICU), a discharge plan is prepared, including educational
activities and exchanges. Larger neonatal units have dedi-
cated discharge planning nurses who may also have
responsibility for the RSV programme. They can provide
parents with an early link into the Synacare programme
and provide ongoing support and education. Close to the
time of discharge, all parents are invited to attend a pre-
discharge class. This class is generally held weekly and
includes a resuscitation demonstration, information
regarding safe sleeping guidelines, RSV exposure preven-
tion, the importance of breastfeeding, preparation of for-
mula feeds, childhood vaccination schedules, and
information regarding follow-up post-discharge. Parents
are provided with take-home material containing infor-
mation from this class. A number of websites containing
useful information regarding RSV are recommended by
nurses [38]. Posters displayed in neonatal unit corridors, in
breastfeeding rooms, and in paediatric outpatient areas are
also used for parental educational purposes. An educational
booklet (in English, French, and Polish) containing infor-
mation on the Synacare programme is provided to par-
ents. In Ireland, parents often use the nurse homecare visit
as an opportunity to ask general child healthcare questions.
In the Netherlands, parental education is mainly pro-
vided by the homecare nurses responsible for administering
palivizumab. The first contact with a homecare nurse often
takes place after discharge from the hospital. At discharge
from the neonatal ward, parents receive an instruction
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booklet (‘‘Home with the baby’’) that provides parents with
information regarding the care of a premature infant. Par-
ents are also able to ask questions regarding homecare at
the infant discharge. At this time, parents are instructed in
ways to minimise their infant’s risk of RSV infection, such
as hand washing and avoidance of exposure to tobacco
smoke, day care, crowded areas, and people who have
symptoms of colds. At this time, parents are also provided
details on the Synacare programme. Educational material
can be found in documents and a website provided by the
Dutch National Institute for Public Health and the Envi-
ronment [39], in informational material supplied by Abb-
Vie, and on websites of parent/guardian support groups
[40, 41]. A specialised magazine, Vroegertje (Little early
starter), and a website, Te Vroeg Geboren (Premature
birth), contain information useful to parents with infants at
risk of severe RSV infection [42]. The magazine is updated
yearly and is distributed to hospitals and ICUs. The
Synacare provider also distributes an information package
(in Dutch, English, French, Turkish, and Arabic) to parents.
The package contains information intended to help parents
reduce the risk of RSV infection and provides useful
websites.
Home service and parental satisfaction
In both countries, surveys were conducted in which the
overall objective of the research was to ascertain the par-
ent’s/guardian’s satisfaction with the Synacare Home
Service. More specifically, data were collected regarding
parental perceptions of the Synacare Home Service,
strengths, weaknesses, and gaps in the Home Service, and
priorities for improvement. Data were collated only from
those contacted or those parents that completed the ques-
tionnaire. The percentage of non-responders was not
collected.
In Ireland, telephone surveys were conducted in 2008
(n = 111), 2009 (n = 100), and 2011 [n = 50 (by 2011, in
Ireland, because of refinements in the service made due to
feedback, a smaller sample size could be used for the
survey)], representing 10–20 % of the total households in
which infants received RSV prophylaxis in that year. Par-
ents of infants who received palivizumab at home were
asked questions to determine their satisfaction with the
homecare service. Overall satisfaction with homecare was
at or near 100 % for the parents contacted for the 3 years in
which surveys were conducted (Fig. 2a). All survey
respondents considered homecare to be superior to hospital
care (Fig. 2b). Respondents felt that homecare directly
saved them &4 h of time and €81 relative to prophylactic
treatment administered at the hospital. The majority of
respondents in 2011 (72 %) cited convenience as the rea-
son for preferring homecare. More than 90 % of respon-
dents stated that various aspects of their experience with
home health nurses were ‘‘excellent’’ in the three surveys
(Fig. 3a–d).
Parental surveys were conducted in the Netherlands by
the nurses at the time of one of the scheduled visits. Parents
were given a questionnaire and asked to anonymously
Table 2 Useful websites for parents and guardians of children at risk for severe RSV infection
International
General RSV information and Q&A from the March of
Dimes
http://www.marchofdimes.com/baby/rsv.aspx
General RSV information from the European
Foundation for the Care of Newborn Infants
http://www.efcni.org/index.php?id=1971
Ireland
Information for parents of premature children http://www.irishprematurebabies.com/
Information for parents of premature children http://www.bliss.org.uk/
The Netherlands
Populations recommended for palivizumab prophylaxis https://zoek.officielebekendmakingen.nl/stcrt-2006-218-p29-SC77527.pdf
RSV information leaflet from the Association of
Parents of Incubator Children
http://www.couveuseouders.nl/data/files/RSV-folder%20ZW%202009.pdf




St. Antonius ‘‘Home With the Baby’’ http://www.antoniusziekenhuis.nl/1822865/1850369/naar_huis_met_baby




Explanation of the Synacare programme http://www.synacare.nl/home
Te Vroeg Geboren http://tevroeggeboren.nl
Q&A questions and answers, RSV respiratory syncytial virus
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complete and return it to the nurse on that day’s visit. For
the winter seasons 2011–2012 and 2012–2013, 970 and
1009 parents completed the questionnaires, respectively,
representing &20 % of the infants who received palivi-
zumab prophylaxis that season. Parents expressed overall
satisfaction with the Synacare programme (from pre-
scription to administration), with 68 % of respondents
choosing the highest rating (‘‘very good’’) and 31 %
choosing ‘‘good’’ in both surveys (Fig. 4a). Most survey
respondents preferred home prophylaxis to receiving
Fig. 2 a Overall satisfaction with the Synacare programme among Irish parents and b preference of homecare vs hospital service. n = 111,
100 and 50 in 2008, 2009 and 2011, respectively
Fig. 3 Satisfaction among Irish parents with the home service nurse
in relation to a how good the nurse is at dealing with the child, b how
thoroughly the nurse examines the child before giving the injection,
c how well the nurse answers my questions, and d arriving on time on
a scale of 1–5, with 5 being excellent. n = 111, 100 and 50 in 2008,
2009 and 2011, respectively
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palivizumab at the doctor’s office or hospital (Fig. 4b).
Most respondents considered the nurse who administered
prophylaxis to be ‘‘very good’’ in both surveys (Fig. 5).
Discussion
Although the homecare systems in Ireland and the
Netherlands differ, they both deliver the same fundamental
service by providing an efficient and appreciated method of
administering palivizumab in the home setting. They also
provide the attending physician with useful updates
regarding the health of the infant, including any AEs, and
allow caregivers the opportunity to speak with a trained
nurse to discuss basic healthcare issues.
Table 1 lists the infants eligible for palivizumab pro-
phylaxis in each country. In the Netherlands, there is
national guidance on infant eligibility [30], whereas in
Ireland, the eligibility criteria are driven by the prescribing
hospital. This explains why, in Ireland, not every infant
meeting the guidelines in Table 1 is eligible for RSV
prophylaxis. In both countries, physicians are entitled to
prescribe at their own clinical discretion, resulting in dif-
ferent prescribing practices throughout each programme.
Several authors have commented that it seems counter-
intuitive that parents would take their infants into a clinic
or even to their doctor’s office to have a prophylactic
injection where they are likely to be exposed to sick chil-
dren in the waiting room [27, 43, 44]. At-home prophylaxis
with palivizumab, as demonstrated in the Synacare pro-
grammes in Ireland and the Netherlands, appears to provide
holistic benefits to at-risk infants and their families. As
with the care of the elderly in their home setting, extremely
vulnerable infants should be extended the benefits of
homecare, where possible.
Furthermore, physicians and parents support the idea of
reducing the number of neonatologist, paediatrician, or
general practitioner visits by five or six (i.e. one visit for
each RSV dose) during the RSV season [44]. A prospective
observational study in the United States reported that
prophylaxis with palivizumab decreased RSV hospitalisa-
tions in at-risk infants, with patients receiving administra-
tion at home having the lowest rates of hospitalisation [45].
Compliance was significantly higher with a home-based
rather than a clinic-based system and was associated with a
decrease in hospitalisations and fewer unscheduled medical
Fig. 4 a Overall satisfaction among Dutch parents with children in
the Synacare programme; no respondents chose ‘‘bad’’, ‘‘inade-
quate’’, or ‘‘moderate’’ options on either survey; 1 % did not complete
this question in both surveys. b Preference for palivizumab
administration in the home setting compared with a doctor’s office
or hospital; 4 % did not complete the survey in 2011–2012 and 2 %
did not complete the survey in 2012–2013. n = 970 and 1009 for the
2011–2012 and 2012–2013 RSV seasons, respectively
Fig. 5 Parents’ ratings of homecare nurses providing Synacare in
the Netherlands. No respondents chose ‘‘bad’’ or ‘‘inadequate’’
options. 1 % of respondents did not complete this question in both
surveys; 1 % of respondents chose ‘‘Moderate’’ in 2012–2013.
n = 970 and 1009 for the 2011–2012 and 2012–2013 RSV seasons,
respectively
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visits [27, 45]. The authors stated that home-based delivery
of RSV prophylaxis may be more efficacious in preventing
disease through increased compliance and decreased
exposure of the high-risk infant to the clinic environment
[27, 45].
Mechanisms to reduce an infant’s risk of serious RSV
infection and to reduce travelling expenses and stress are
especially important because parents of premature children
have often already experienced a number of stressful situ-
ations involving the infant (i.e. neonatal ICU stay,
mechanical ventilation, supplemental oxygen requirement),
and/or possible maternal adverse health events (i.e. ruptured
membranes that may have led to the premature birth of the
child). These stressful experiences may continue to impact
parents through the first year of the infant’s life and beyond.
For a number of conditions, treatment of patients using a
homecare model has been shown to have both clinical and
economic advantages compared with traditional care in a
hospital, clinic, or physician’s office [46–48]. The admin-
istration of palivizumab using a homecare model has been
shown to increase compliance, which is expected to reduce
RSV-associated lower respiratory tract disease hospitali-
sations [26, 45]. At-home palivizumab administration in
Ireland and the Netherlands, through the Synacare pro-
gramme, would be expected to have similar clinical (and
economic) advantages over administration in the hospital.
In both the Netherlands and Ireland, the Synacare
service is fully funded by AbbVie, the supplier of palivi-
zumab. In Ireland,[3500 infants have been treated during
the 5 years of the Synacare programme, resulting in an
estimated decrease of hospital outpatient appointments of
&14,000 [49]. This decrease in workload for palivizumab
administration frees up time at the clinic/hospital for the
already overstretched nurses and other medical staff in the
clinics. It is difficult to quantify the cost savings to the
healthcare system; however, using the cost of one vacci-
nation visit, as detailed by the Health Service Executive of
Ireland, of €42.75 per general practitioner visit [50], this
would result in a cost saving of €595,500. Likewise, in the
Netherlands, the cost of one general practitioner visit
would be €18.08 plus materials [51] and a hospitalisation
treatment visit of a newborn child in neonatology would be
€190.00 [52]. In addition, the time required for the parents
to take the infant to the hospital and wait in a paediatric
ward is not required. A study is ongoing in Ireland to
quantify the total cost savings of the Synacare pro-
gramme, including the costs of potential increased wastage
of palivizumab due to lost batching opportunities (i.e. the
use of a single medication vial to treat multiple eligible
children). In addition, this study will review compliance
and efficacy, comparing RSV seasonal clinical outcome
data before and after the introduction of the Synacare
programme in Ireland.
Homecare also allows parents a greater opportunity
for interaction with the visiting nurse, with more time for
questions and answers in their own familiar home
environment. Parental survey responses demonstrate
parental satisfaction with the Synacare programme and
with the nurses who provide the care. As an added
benefit, in-home prophylaxis is less stressful for the
child. Before home administration, infants were brought
to busy outpatient departments, with visits often taking
up to 2 hours.
At-home prophylaxis of palivizumab, as demonstrated
in the Synacare programmes in Ireland and the Nether-
lands, appears to provide both clinical benefits to at-risk
infants and their families and economic benefits to regional
healthcare systems. Although more formal studies com-
paring homecare with hospital palivizumab prophylaxis
may be necessary to determine any potential clinical and/or
economic advantages, the information provided here sug-
gests that additional countries may derive benefit from
programmes such as Synacare.
Conclusion
In summary, both the Irish and the Netherlands homecare
systems consist of the following key elements critical to
their success:
• Agreement and trust between the hospital caregivers
and homecare providers. This is based on open
communication and feedback on patient status to the
hospital care team.
• An organised appointment set-up process to meet
parents’ needs and schedules and to ensure the most
optimal use of the home nurses’ time.
• Well-trained home nurses to provide the RSV prophy-
laxis, to review and report on the infant’s general
health, and to ensure that parents have all of the
information necessary to help prevent RSV infection.
• Ongoing review to ensure that the health of the infant
and the value of the service to the parents are as good as
possible year after year.
• Removal of hospital outpatient visits from the health-
care system, with avoidance of monthly visits for each
infant receiving palivizumab prophylaxis.
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